Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Heart Failure: A Comprehensive Review of Literature
Type 2 diabetes mellitus (T2DM) is highly prevalent in the modern world due to a rise in obesity. Diabetes can give rise to many secondary ailments among which heart failure is the most common. Heart failure brings about confirmatory changes in the myocardium which shifts the metabolism from gluco...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Liaquat National Hospital and Medical College
2024-04-01
|
| Series: | Liaquat National Journal of Primary Care |
| Subjects: | |
| Online Access: | https://journals.lnh.edu.pk/lnjpc/pdf/89d9d8a8-970c-4a3a-bb32-d5388457e892.pdf |
| Summary: | Type 2 diabetes mellitus (T2DM) is highly prevalent in the modern world due to a rise in obesity. Diabetes can give rise to many
secondary ailments among which heart failure is the most common. Heart failure brings about confirmatory changes in the
myocardium which shifts the metabolism from glucose to fatty acid which further impairs cardiac function. Among the antidiabetic
agents, SGLT2 inhibitors such as empagliflozin and dapagliflozin have decreased heart failure exacerbations even in the absence
of diabetes. We employed search engines such as Google Scholar, MEDLINE, and Euro PMC for our article search. The keywords
such as heart failure, SGLT2 inhibitors, and diabetes were used. Duplicate studies were excluded during our analysis. According to
the literature, several theories have been put forward on the mechanisms through which SGLT2 inhibitors can work in heart failure.
Mainly they work by lowering blood pressure, improvement of cardiac energy metabolism, anti-inflammatory effect, protecting from
cardiac remodeling, diuresis, and natriuretic effects. |
|---|---|
| ISSN: | 2707-3521 2708-9134 |